ALMS

Alumis Inc

• Simply Wall St·1d ago

  How Alumis’ Revenue Slide but Smaller Per-Share Loss Will Impact Alumis (ALMS) Investors

• The Motley Fool·2d ago

  This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter

• Dow Jones·05/19 12:36

  Alumis Is Maintained at Buy by Chardan Capital

• Dow Jones·05/19 12:36

  Alumis Price Target Raised to $40.00/Share From $38.00 by Chardan Capital

• Benzinga·05/19 12:26

  Chardan Capital Maintains Buy on Alumis, Raises Price Target to $40

• TipRanks·05/19 12:01

  Alumis price target raised to $40 from $38 at Chardan

• PUBT·05/18 20:28

  Alumis announces annual shareholder meeting

• Simply Wall St·05/18 11:24

  Assessing Alumis (ALMS) Valuation After Positive Phase 3 Envudeucitinib Data And Upcoming Regulatory Milestones

• The Motley Fool·05/17 18:33

  Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter

• Simply Wall St·05/16 19:21

  Should Alumis’ (ALMS) Envudeucitinib-Centric Strategy After Q1 Losses Require Action From Investors?

• The Motley Fool·05/15 22:56

  Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back

• Benzinga·05/15 15:49

  This Unity Bancorp Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday

• TipRanks·05/15 15:26

  Alumis Inc. (ALMS) Gets a Buy from Leerink Partners

• Dow Jones·05/15 13:14

  Alumis Is Maintained at Overweight by Wells Fargo

• Benzinga·05/15 13:03

  Wells Fargo Maintains Overweight on Alumis, Raises Price Target to $51